These results suggest that MUC16 mutation in the primary tumor is a poor prognostic factor for ESCC patients with LNM, and those patients with LNM harboring MUC16 mutation have a higher risk of relapse. This evidence concerns the gene MUC16 and esophageal squamous cell carcinoma.